PE and DVT from probability to treatment

1. A. Reassess probability and use D-dimer or imaging as the resulting pathway indicates (Best answer)

   1. Which newly disclosed PERC criterion is positive?

      A history of objectively confirmed VTE.

   2. Can the all-negative PERC exit still be used?

      No. One positive criterion removes that exit.

   3. Does that positive criterion itself diagnose PE or mandate CT?

      No. The complete probability assessment determines the next pathway.

   4. What follows?

      Reassess probability, then use the appropriate D-dimer or imaging branch.

   Read the complete explanation

   A positive PERC item removes that no-testing exit but does not determine the whole next pathway. Prior VTE matters even with normal pulse and oxygen saturation. Failure of a rule-out screen is a reason for further assessment, not a diagnosis.

2. B. Proceed directly to CT solely because of the positive PERC item (Why this does not fit)

   1. What assessment can justify proceeding directly to CT?

      High clinical probability or other pathway findings can justify immediate imaging.

   2. Does one positive PERC item establish that probability by itself?

      One positive PERC item alone does not establish high probability.

   3. How should this distinction guide a similar patient?

      Choose the next test from the complete probability assessment.

   Read the complete explanation

   High clinical probability or other pathway findings can justify immediate imaging. One positive PERC item alone does not establish high probability. Choose the next test from the complete probability assessment.

3. C. Begin anticoagulation solely on the revised screening result (Why this does not fit)

   1. When might treatment begin before imaging?

      Empiric treatment may be appropriate when suspicion, delay and bleeding risk justify it.

   2. Does failure of PERC exclusion itself prove an acute clot?

      The new history invalidates PERC exclusion but does not establish an acute clot.

   3. How should this distinction guide a similar patient?

      Separate screening eligibility from the threshold for treatment.

   Read the complete explanation

   Empiric treatment may be appropriate when suspicion, delay and bleeding risk justify it. The new history invalidates PERC exclusion but does not establish an acute clot. Separate screening eligibility from the threshold for treatment.

4. D. End the PE evaluation using the unchanged low-risk rule (Why this does not fit)

   1. What must be true of all PERC criteria to use its exit?

      A very-low-risk patient can avoid testing when all PERC criteria are negative.

   2. What did the newly disclosed prior DVT change?

      The newly disclosed prior DVT makes one criterion positive.

   3. How should this distinction guide a similar patient?

      Recheck rule eligibility when the history changes.

   Read the complete explanation

   A very-low-risk patient can avoid testing when all PERC criteria are negative. The newly disclosed prior DVT makes one criterion positive. Recheck rule eligibility when the history changes.

Takeaway: Failure of a rule-out screen is a reason for further assessment, not a diagnosis.

Case sources: [1] [3]

1. A. Proximal DVT; assess and initiate therapeutic anticoagulation (Best answer)

   1. Which vessel fails to compress?

      The femoral vein, a proximal deep vein.

   2. Does a patent adjacent artery remove that venous finding?

      No. Arterial inflow and venous outflow are separate questions.

   3. What diagnosis fits the acute symptoms and positive compression finding?

      Proximal DVT.

   4. What treatment direction follows after routine suitability assessment?

      Therapeutic anticoagulation, because no major constraint is supplied.

   Read the complete explanation

   A noncompressible proximal deep vein in this acute context supports DVT. The femoral finding matches the symptoms and no major treatment constraint is supplied. Confirm location, then assess bleeding and drug suitability before treatment.

2. B. Isolated superficial thrombophlebitis; use local symptom treatment (Why this does not fit)

   1. Which vascular compartment defines superficial thrombophlebitis?

      Superficial thrombophlebitis affects superficial veins, rather than the proximal deep venous system.

   2. Is the femoral vein in that compartment?

      The femoral vein is a deep proximal vein.

   3. How should this distinction guide a similar patient?

      Name the affected vessel before choosing the treatment pathway.

   Read the complete explanation

   Superficial-vein thrombosis has a different anatomic extent and treatment assessment. The femoral vein is a deep proximal vein. Name the affected vessel before choosing the treatment pathway.

3. C. An inconclusive venous study; repeat ultrasound before treatment (Why this does not fit)

   1. When does an inconclusive examination call for repeat imaging?

      A technically limited or equivocal study can need repeat imaging.

   2. Is the symptomatic proximal vein finding equivocal here?

      The supplied examination demonstrates noncompressibility in the symptomatic proximal deep vein.

   3. How should this distinction guide a similar patient?

      Use a clear positive finding differently from an incomplete negative study.

   Read the complete explanation

   A technically limited or equivocal study can need repeat imaging. The supplied examination demonstrates noncompressibility in the symptomatic proximal deep vein. Use a clear positive finding differently from an incomplete negative study.

4. D. Acute limb ischemia; prioritize arterial embolectomy (Why this does not fit)

   1. What lesion leads to arterial embolectomy?

      Arterial occlusion can threaten a limb and require urgent revascularization.

   2. Which vessel is abnormal and which remains patent?

      The abnormality is in the vein and the adjacent artery is patent.

   3. How should this distinction guide a similar patient?

      Separate venous obstruction from arterial inflow failure.

   Read the complete explanation

   Arterial occlusion can threaten a limb and require urgent revascularization. The abnormality is in the vein and the adjacent artery is patent. Separate venous obstruction from arterial inflow failure.

5. E. Isolated distal DVT; consider surveillance based on extension risk (Why this does not fit)

   1. Where is an isolated distal DVT located?

      Isolated distal DVT involves calf deep veins below the popliteal vein.

   2. Does a femoral clot belong to the calf-vein category?

      The clot is in the femoral vein, proximal to the calf-vein territory.

   3. How should this distinction guide a similar patient?

      Proximal and distal DVT are different treatment categories.

   Read the complete explanation

   Selected calf-vein thromboses can be managed with serial imaging. The clot is in the femoral vein, proximal to the calf-vein territory. Proximal and distal DVT are different treatment categories.

Takeaway: Confirm location, then assess bleeding and drug suitability before treatment.

Case sources: [1] [4]

1. A. Give systemic thrombolysis immediately followed by anticoagulation (Why this does not fit)

   1. When can systemic lysis have a favorable benefit–risk balance?

      Systemic lysis can be lifesaving in appropriately selected high-risk PE.

   2. Does this patient currently have shock or hypoperfusion?

      The patient has no current shock or hypoperfusion, and routine lysis adds major bleeding risk.

   3. How should this distinction guide a similar patient?

      RV injury alone does not establish that immediate lysis has a favorable balance.

   Read the complete explanation

   Systemic lysis can be lifesaving in appropriately selected high-risk PE. The patient has no current shock or hypoperfusion, and routine lysis adds major bleeding risk. RV injury alone does not establish that immediate lysis has a favorable balance.

2. B. Discharge with a DOAC and early routine outpatient review (Why this does not fit)

   1. What profile supports outpatient PE treatment?

      Outpatient care is appropriate for carefully selected low-risk PE.

   2. How do RV dilation and troponin change that assessment?

      RV dilation and positive troponin make a low-risk outpatient assumption inappropriate.

   3. How should this distinction guide a similar patient?

      Normal blood pressure is only one part of disposition assessment.

   Read the complete explanation

   Outpatient care is appropriate for carefully selected low-risk PE. RV dilation and positive troponin make a low-risk outpatient assumption inappropriate. Normal blood pressure is only one part of disposition assessment.

3. C. Anticoagulate in a monitored inpatient setting and reassess for deterioration (Best answer)

   1. What findings prevent a simple low-risk assumption?

      RV dilation and a positive troponin.

   2. What do lactate, warm extremities and blood pressure say about current perfusion?

      No current hypoperfusion or shock is demonstrated.

   3. Which treatment is foundational now?

      Therapeutic anticoagulation.

   4. What setting and contingency fit the increased risk?

      Monitored inpatient care with reassessment and rescue escalation if deterioration develops.

   Read the complete explanation

   RV dysfunction and injury markers raise concern even before shock develops. Current perfusion is stable, supporting anticoagulation and monitoring rather than routine immediate reperfusion. Use both current physiology and deterioration risk to choose the setting of care.

4. D. Arrange catheter thrombectomy before starting anticoagulation (Why this does not fit)

   1. What severity or trajectory can justify catheter intervention?

      Catheter intervention is considered for selected severe or deteriorating PE presentations.

   2. Is that intervention need established by the present stable perfusion?

      Stable perfusion without escalating support does not establish a routine need for upfront thrombectomy.

   3. How should this distinction guide a similar patient?

      Match an invasive intervention to the severity and trajectory demonstrated.

   Read the complete explanation

   Catheter intervention is considered for selected severe or deteriorating PE presentations. Stable perfusion without escalating support does not establish a routine need for upfront thrombectomy. Match an invasive intervention to the severity and trajectory demonstrated.

5. E. Use prophylactic anticoagulation until RV size normalizes (Why this does not fit)

   1. What situation is prophylactic dosing designed for?

      Prophylactic dosing prevents VTE in selected patients without established events.

   2. Does confirmed PE fit that preventive indication?

      PE is confirmed and requires therapeutic anticoagulation unless contraindicated.

   3. How should this distinction guide a similar patient?

      The presence of a clot determines treatment intensity, not the absence of hypotension.

   Read the complete explanation

   Prophylactic dosing prevents VTE in selected patients without established events. PE is confirmed and requires therapeutic anticoagulation unless contraindicated. The presence of a clot determines treatment intensity, not the absence of hypotension.

Takeaway: Use both current physiology and deterioration risk to choose the setting of care.

Case sources: [2] [8] [11]

1. A. Obtain CT pulmonary angiography promptly (Best answer)

   1. Which probability branch do the recent surgery, tachycardia and DVT signs support?

      With PE judged more likely than an alternative, the supplied assessment is PE likely.

   2. Is D-dimer the exclusion step for that branch?

      No. The likely-PE pathway proceeds to appropriate imaging.

   3. What supplied constraints favorCTPA?

      CT is available, kidney function is adequate and there is no contrast allergy.

   4. What is the next action?

      Obtain CTPA promptly while continuing clinical assessment.

   Read the complete explanation

   CTPA directly evaluates pulmonary arteries in a likely-PE pathway when suitable. Multiple clinical risk findings establish the pathway, and the stated constraints permit CT. A likely-PE assessment leads to appropriate imaging rather than screening D-dimer.

2. B. Use ventilation-perfusion imaging as the initial test (Why this does not fit)

   1. When is V/Q a useful initial imaging choice?

      V/Q imaging is useful when CT contrast is unsuitable or other circumstances favor it.

   2. Are the relevant CT constraints present here?

      CT is available and no kidney or contrast limitation is supplied.

   3. How should this distinction guide a similar patient?

      Match imaging to probability, patient constraints and availability.

   Read the complete explanation

   V/Q imaging is useful when CT contrast is unsuitable or other circumstances favor it. CT is available and no kidney or contrast limitation is supplied. Match imaging to probability, patient constraints and availability.

3. C. Obtain D-dimer and reserve imaging for a positive result (Why this does not fit)

   1. In which probability group can D-dimer help exclude PE?

      D-dimer exclusion is useful in selected low or unlikely clinical-probability pathways.

   2. Which probability branch do these combined findings establish?

      The supplied findings place this patient in the likely-PE pathway.

   3. How should this distinction guide a similar patient?

      Establish probability before selecting a rule-out assay.

   Read the complete explanation

   D-dimer exclusion is useful in selected low or unlikely clinical-probability pathways. The supplied findings place this patient in the likely-PE pathway. Establish probability before selecting a rule-out assay.

4. D. Use bedside echocardiography as the initial exclusion test (Why this does not fit)

   1. What does echo assess in PE?

      Echo helps assess RV stress, especially in an unstable patient.

   2. Could a normal echo reliably exclude clot in this stable patient?

      This stable patient needs diagnostic pulmonary imaging; a normal echo would not reliably exclude PE.

   3. How should this distinction guide a similar patient?

      Distinguish hemodynamic assessment from clot exclusion.

   Read the complete explanation

   Echo helps assess RV stress, especially in an unstable patient. This stable patient needs diagnostic pulmonary imaging; a normal echo would not reliably exclude PE. Distinguish hemodynamic assessment from clot exclusion.

5. E. Repeat compression ultrasound in one week before pulmonary testing (Why this does not fit)

   1. What uncertainty does serial leg ultrasound address?

      Serial ultrasound can resolve selected negative initial DVT studies.

   2. Would waiting resolve the current likely-PE chest presentation safely?

      Acute chest symptoms and a likely-PE assessment require a pulmonary diagnostic plan now.

   3. How should this distinction guide a similar patient?

      Do not substitute a delayed leg pathway for current suspected PE.

   Read the complete explanation

   Serial ultrasound can resolve selected negative initial DVT studies. Acute chest symptoms and a likely-PE assessment require a pulmonary diagnostic plan now. Do not substitute a delayed leg pathway for current suspected PE.

Takeaway: A likely-PE assessment leads to appropriate imaging rather than screening D-dimer.

Case sources: [1] [3]

1. A. Obtain leg ultrasound before ending the PE pathway (Why this does not fit)

   1. What additional question can leg ultrasound answer?

      Ultrasound is useful for suspected DVT and some alternative diagnostic strategies.

   2. Is an unresolved leg question supplied after this eligible negative pathway?

      No leg finding is supplied and the selected PE exclusion pathway is satisfied.

   3. How should this distinction guide a similar patient?

      Order the next test for a remaining clinical question, not an isolated flagged laboratory value.

   Read the complete explanation

   Ultrasound is useful for suspected DVT and some alternative diagnostic strategies. No leg finding is supplied and the selected PE exclusion pathway is satisfied. Order the next test for a remaining clinical question, not an isolated flagged laboratory value.

2. B. Obtain CTPA because the result exceeds 500 ng/mL FEU (Why this does not fit)

   1. When is the conventional 500 threshold the applicable cutoff?

      The conventional cutoff is used where age adjustment is not part of the selected pathway.

   2. Which validated cutoff does this service use for this 74-year-old?

      The validated age-adjusted cutoff here is 74 × 10 = 740 ng/mL FEU; 680 is below it.

   3. How should this distinction guide a similar patient?

      Apply one validated pathway consistently.

   Read the complete explanation

   The conventional cutoff is used where age adjustment is not part of the selected pathway. This service explicitly uses a validated age-adjusted pathway for this patient. Apply one validated pathway consistently.

3. C. Repeat D-dimer the next day before deciding on imaging (Why this does not fit)

   1. When would a repeat assay resolve a genuine uncertainty?

      Repeat testing may be needed when a sample or clinical assessment is unreliable.

   2. Is a sample problem or clinical change supplied?

      No sample problem or new clinical change is supplied; the current eligible result is below threshold.

   3. How should this distinction guide a similar patient?

      Do not add serial tests without a defined unresolved question.

   Read the complete explanation

   Repeat testing may be needed when a sample or clinical assessment is unreliable. No sample problem or new clinical change is supplied; the current eligible result is below threshold. Do not add serial tests without a defined unresolved question.

4. D. End PE-specific testing and investigate other causes of dyspnea (Best answer)

   1. Is this patient in the pathway's eligible probability group?

      Yes. The Wells assessment is PE unlikely.

   2. What is 74 times 10?

      The age-adjusted threshold is 740 ng/mL FEU.

   3. How does 680 compare with 740?

      It is below the validated threshold.

   4. What pathway endpoint follows?

      End PE-specific testing and investigate other causes of dyspnea, unless the clinical situation changes.

   Read the complete explanation

   A result below the validated adjusted threshold can exclude PE in an eligible unlikely-probability pathway. The threshold is 740 and the measured value is 680 ng/mL FEU. Check probability, age, assay units and threshold together.

Takeaway: Check probability, age, assay units and threshold together.

Case sources: [1] [3]

1. A. Assess alternative diagnoses and advise return for persistent or worsening symptoms (Best answer)

   1. What does a two-level DVT Wells score 1 mean?

      DVT is unlikely in the stated pathway.

   2. Is the negative assay interpretable here?

      Yes. No prior anticoagulation or sample problem is supplied.

   3. What does that combination permit?

      Stop this DVT investigation and consider alternative diagnoses.

   4. What advice preserves safety as symptoms evolve?

      Return for persistent or worsening symptoms that require reassessment.

   Read the complete explanation

   A negative D-dimer in an eligible unlikely-DVT pathway makes DVT unlikely enough to stop that investigation. Both the probability score and assay support the pathway endpoint. End a completed rule-out pathway while preserving follow-up for a changing presentation.

2. B. Schedule serial proximal ultrasound at six to eight days (Why this does not fit)

   1. Which result combination calls for serial proximal scanning?

      Serial scanning is used after specific combinations of likely probability, negative proximal scan and positive D-dimer.

   2. Does this patient have that combination?

      That combination is absent; this is an unlikely-DVT negative-assay pathway.

   3. How should this distinction guide a similar patient?

      Use the follow-up schedule belonging to the pathway actually entered.

   Read the complete explanation

   Serial scanning is used after specific combinations of likely probability, negative proximal scan and positive D-dimer. That combination is absent; this is an unlikely-DVT negative-assay pathway. Use the follow-up schedule belonging to the pathway actually entered.

3. C. Begin interim therapeutic anticoagulation while awaiting a repeat assay (Why this does not fit)

   1. When can diagnostic delay justify interim anticoagulation?

      Interim treatment can be indicated when required diagnostic tests are delayed.

   2. Is the required exclusion test still pending here?

      The supplied pathway already has a timely interpretable negative result.

   3. How should this distinction guide a similar patient?

      Diagnostic delay and a completed negative pathway are different situations.

   Read the complete explanation

   Interim treatment can be indicated when required diagnostic tests are delayed. The supplied pathway already has a timely interpretable negative result. Diagnostic delay and a completed negative pathway are different situations.

4. D. Obtain immediate proximal compression ultrasound (Why this does not fit)

   1. Which branches call for proximal ultrasound?

      Ultrasound is indicated after a positive D-dimer in the unlikely pathway or in a likely-DVT pathway.

   2. Does a Wells score 1 with a negative assay enter one of them?

      This patient has an interpretable negative assay in the unlikely group.

   3. How should this distinction guide a similar patient?

      Combine the test with its intended probability category.

   Read the complete explanation

   Ultrasound is indicated after a positive D-dimer in the unlikely pathway or in a likely-DVT pathway. This patient has an interpretable negative assay in the unlikely group. Combine the test with its intended probability category.

Takeaway: End a completed rule-out pathway while preserving follow-up for a changing presentation.

Case sources: [1]

1. A. Repeat D-dimer in six to eight days instead of ultrasound (Why this does not fit)

   1. Does D-dimer localize an evolving proximal clot?

      D-dimer indicates fibrin turnover but does not localize evolving thrombosis.

   2. What uncertainty must the follow-up actually resolve?

      The unresolved question is whether proximal thrombosis becomes demonstrable.

   3. How should this distinction guide a similar patient?

      Use imaging to resolve a serial-imaging question.

   Read the complete explanation

   D-dimer indicates fibrin turnover but does not localize evolving thrombosis. The unresolved question is whether proximal thrombosis becomes demonstrable. Use imaging to resolve a serial-imaging question.

2. B. Obtain CT venography immediately as routine follow-up (Why this does not fit)

   1. When can CT venography help with venous assessment?

      Cross-sectional venous imaging can help selected anatomic or technically limited cases.

   2. Is a technical or pelvic-anatomic limitation supplied?

      No technical limitation or pelvic-obstruction concern is supplied; the stated pathway uses repeat proximal ultrasound.

   3. How should this distinction guide a similar patient?

      Reserve alternative imaging for a specific unresolved limitation.

   Read the complete explanation

   Cross-sectional venous imaging can help selected anatomic or technically limited cases. No technical limitation or pelvic-obstruction concern is supplied; the stated pathway uses repeat proximal ultrasound. Reserve alternative imaging for a specific unresolved limitation.

3. C. Repeat proximal compression ultrasound in six to eight days (Best answer)

   1. Which ultrasound strategy is being used?

      The NICE proximal-ultrasound pathway, not a whole-leg strategy.

   2. What remains unresolved after a negative proximal scan and positiveD-dimer?

      Proximal thrombosis may need serial reassessment.

   3. When should the repeat proximal scan occur?

      Six to eight days later.

   4. What makes the interval meaningful?

      It belongs to this specific result combination and imaging pathway.

   Read the complete explanation

   NICE specifies a repeat proximal scan for this result combination. The likely score, positive D-dimer and negative proximal scan match that branch. Interpret a negative scan in the context of both technique and pathway.

4. D. End DVT follow-up after the single proximal scan (Why this does not fit)

   1. What decision is reasonable after the entire validated pathway is negative?

      A completed negative diagnostic pathway can allow testing to stop.

   2. What role does the positive D-dimer have after this proximal scan?

      Positive D-dimer after a negative proximal scan in this pathway calls for repeat imaging.

   3. How should this distinction guide a similar patient?

      Know whether the chosen ultrasound strategy requires serial assessment.

   Read the complete explanation

   A completed negative diagnostic pathway can allow testing to stop. Positive D-dimer after a negative proximal scan in this pathway calls for repeat imaging. Know whether the chosen ultrasound strategy requires serial assessment.

Takeaway: Interpret a negative scan in the context of both technique and pathway.

Case sources: [1]

1. A. Use bedside echocardiography to end the diagnostic workup if normal (Why this does not fit)

   1. What does a normal RV assessment tell you about a stable PE?

      Normal RV findings do not reliably exclude stable PE; echo primarily assesses cardiac consequences.

   2. Would it resolve the pulmonary clot question?

      A stable PE can occur without diagnostic echo abnormalities.

   3. How should this distinction guide a similar patient?

      A consequence test is not a reliable exclusion test for the clot itself.

   Read the complete explanation

   Echo assesses RV consequences and helps in unstable presentations. A stable PE can occur without diagnostic echo abnormalities. A consequence test is not a reliable exclusion test for the clot itself.

2. B. Use CTPA after routine contrast premedication as the first choice (Why this does not fit)

   1. Does premedication remove all the supplied contrast constraints?

      Premedication does not remove all contrast-related risk or resolve this patient’s severe renal impairment.

   2. Is a suitable contrast-sparing alternative already available?

      A suitable contrast-sparing alternative is available with favorable chest imaging.

   3. How should this distinction guide a similar patient?

      Do not treat premedication as removal of all contrast-related risk.

   Read the complete explanation

   CTPA is useful when its diagnostic benefit justifies contrast risk; premedication may be considered in selected cases. A suitable contrast-sparing alternative is available with favorable chest imaging. Do not treat premedication as removal of all contrast-related risk.

3. C. Obtain a ventilation-perfusion scan (Best answer)

   1. What two supplied findings make iodinated contrast problematic?

      Severe renal impairment and prior contrast anaphylaxis.

   2. Which available pulmonary test avoids iodinated contrast?

      V/Q scanning.

   3. What makes its interpretation more favorable here?

      A near-normal chest radiograph.

   4. Which initial strategy fits both constraints and availability?

      Obtain the available V/Q study.

   Read the complete explanation

   V/Q imaging evaluates regional ventilation and perfusion without iodinated contrast. Contrast risks are substantial, the film is near normal and V/Q is available. Choose the diagnostic modality using both contraindications and likely interpretability.

4. D. Use compression ultrasound alone and stop if it is negative (Why this does not fit)

   1. What does a positive leg study establish?

      A positive leg study can establish VTE in some diagnostic strategies.

   2. Would a negative leg study exclude clot in the lung?

      A negative leg scan would not exclude PE; an appropriate pulmonary test is available.

   3. How should this distinction guide a similar patient?

      A negative study of one vascular territory does not exclude clot in another.

   Read the complete explanation

   A positive leg study can establish VTE in some diagnostic strategies. A negative leg scan would not exclude PE; an appropriate pulmonary test is available. A negative study of one vascular territory does not exclude clot in another.

5. E. Use unenhanced chest CT to exclude pulmonary arterial clot (Why this does not fit)

   1. What can unenhanced chest CT assess?

      Noncontrast CT can evaluate some alternative thoracic disease.

   2. Does it provide the arterial opacification needed for this exclusion study?

      It does not provide the required contrast opacification for a reliable pulmonary arterial exclusion study.

   3. How should this distinction guide a similar patient?

      Select imaging that answers the actual vascular question.

   Read the complete explanation

   Noncontrast CT can evaluate some alternative thoracic disease. It does not provide the required contrast opacification for a reliable pulmonary arterial exclusion study. Select imaging that answers the actual vascular question.

Takeaway: Choose the diagnostic modality using both contraindications and likely interpretability.

Case sources: [1] [3]

1. A. Repeat the same V/Q study after a bronchodilator dose (Why this does not fit)

   1. When might improving ventilation change a scan's usefulness?

      Improving reversible ventilation may help some lung-function measures.

   2. Does repeating the limited modality best resolve the remaining question here?

      Marked underlying abnormalities have already limited the test, while another suitable modality is available.

   3. How should this distinction guide a similar patient?

      Resolve a known diagnostic limitation with an appropriate alternative test.

   Read the complete explanation

   Improving reversible ventilation may help some lung-function measures. Marked underlying abnormalities have already limited the test, while another suitable modality is available. Resolve a known diagnostic limitation with an appropriate alternative test.

2. B. Obtain CT pulmonary angiography (Best answer)

   1. Has the V/Q report resolved the PE question?

      No. It is indeterminate in an abnormal lung.

   2. Does a negative proximal leg study exclude pulmonary clot?

      No. It examines a different vascular territory.

   3. What suitable alternative can answer the pulmonary question?

      CTPA, because kidney function and contrast history permit it.

   4. What is the general pathway rule?

      Resolve meaningful residual uncertainty rather than call an indeterminate test negative or positive.

   Read the complete explanation

   CTPA can resolve a nondiagnostic V/Q result when contrast is suitable. The unresolved pulmonary question remains after the negative leg study, and CT constraints are absent. Continue until the clinical question is resolved by a valid diagnostic pathway.

3. C. End PE testing because the defects are matched (Why this does not fit)

   1. What can matched defects suggest about underlying lung disease?

      Matched defects may reflect underlying lung disease rather than a classic embolic mismatch.

   2. Has the complete scan actually excluded PE?

      The report remains indeterminate and clinical concern persists.

   3. How should this distinction guide a similar patient?

      Interpret the complete scan category and probability, not one pattern in isolation.

   Read the complete explanation

   Matched defects may reflect underlying lung disease rather than a classic embolic mismatch. The report remains indeterminate and clinical concern persists. Interpret the complete scan category and probability, not one pattern in isolation.

4. D. Diagnose PE from the perfusion abnormalities and start a long-term plan (Why this does not fit)

   1. What scan interpretation can support a positive PE diagnosis?

      High-probability mismatched patterns can support PE in the appropriate context.

   2. Is this scan in that diagnostic category?

      The scan is explicitly indeterminate with matched defects.

   3. How should this distinction guide a similar patient?

      Do not promote an indeterminate result into a positive diagnosis.

   Read the complete explanation

   High-probability mismatched patterns can support PE in the appropriate context. The scan is explicitly indeterminate with matched defects. Do not promote an indeterminate result into a positive diagnosis.

Takeaway: Continue until the clinical question is resolved by a valid diagnostic pathway.

Case sources: [3]

1. A. Proceed to appropriately optimized CTPA after counseling (Best answer)

   1. Has the negative leg study resolved the pulmonary concern?

      No. PE remains under consideration.

   2. What makes the available V/Q study less useful?

      Substantial parenchymal abnormalities on the chest radiograph limit expected interpretation.

   3. Is aCTPA constraint supplied?

      No. Kidney function is normal and no contrast allergy is present.

   4. What plan follows after counseling?

      Proceed to appropriately optimized CTPA rather than defer indicated pulmonary imaging because of pregnancy alone.

   Read the complete explanation

   CTPA is a diagnostic option in pregnancy when pulmonary imaging is indicated. The abnormal radiograph limits V/Q usefulness and no CT contrast barrier is supplied. Choose a test likely to answer the question while discussing its risks.

2. B. Use echocardiography and end testing if RV size is normal (Why this does not fit)

   1. What cardiac consequence can echo detect?

      Echo can detect RV dilation or dysfunction associated with an increased pulmonary vascular load.

   2. Could a normal RV exclude the stable pulmonary clot being considered?

      A normal RV would not exclude a stable pulmonary embolus.

   3. How should this distinction guide a similar patient?

      Evaluate the clot with a suitable diagnostic pathway, not only its cardiac consequences.

   Read the complete explanation

   Echo can assess hemodynamic consequences of PE. A normal RV would not exclude a stable pulmonary embolus. Evaluate the clot with a suitable diagnostic pathway, not only its cardiac consequences.

3. C. Use the available V/Q study regardless of the expected limitation (Why this does not fit)

   1. What chest-film context often favors V/Q in pregnancy?

      V/Q is often useful in pregnancy, particularly with a normal chest radiograph.

   2. What supplied finding instead limits its expected quality?

      Substantial parenchymal abnormalities make the supplied service expect poor interpretability.

   3. How should this distinction guide a similar patient?

      Pregnancy imaging choices depend on the actual film and local test quality.

   Read the complete explanation

   V/Q is often useful in pregnancy, particularly with a normal chest radiograph. Substantial parenchymal abnormalities make the supplied service expect poor interpretability. Pregnancy imaging choices depend on the actual film and local test quality.

4. D. Repeat leg ultrasound in one week before pulmonary imaging (Why this does not fit)

   1. What diagnostic pathway can use serial leg imaging?

      Serial leg ultrasound can be appropriate in a DVT pathway.

   2. Does it answer the current pulmonary question after a negative leg scan?

      The current unresolved problem is suspected pulmonary embolism in pregnancy.

   3. How should this distinction guide a similar patient?

      Do not let a negative test in another territory postpone necessary pulmonary evaluation.

   Read the complete explanation

   Serial leg ultrasound can be appropriate in a DVT pathway. The current unresolved problem is suspected pulmonary embolism in pregnancy. Do not let a negative test in another territory postpone necessary pulmonary evaluation.

Takeaway: Choose a test likely to answer the question while discussing its risks.

Case sources: [3] [6] [7]

1. A. Oral warfarin adjusted to a therapeutic INR (Why this does not fit)

   1. Can warfarin effectively treat VTE outside pregnancy?

      Warfarin is effective for many nonpregnant VTE indications.

   2. What separate fetal concern changes its suitability here?

      Fetal risks make it unsuitable for routine pregnancy-associated VTE treatment here.

   3. How should this distinction guide a similar patient?

      Maternal efficacy does not settle fetal safety.

   Read the complete explanation

   Warfarin is effective for many nonpregnant VTE indications. Fetal risks make it unsuitable for routine pregnancy-associated VTE treatment here. Maternal efficacy does not settle fetal safety.

2. B. Intravenous unfractionated heparin throughout the remaining pregnancy (Why this does not fit)

   1. Which clinical constraints can favor UFH?

      Severe renal impairment or a need for rapid interruption and reversal, such as an imminent procedure or delivery, can favor UFH.

   2. Are those constraints present at 20 weeks with normal kidneys?

      Normal kidneys and no imminent delivery make prolonged infusion less suitable than LMWH.

   3. How should this distinction guide a similar patient?

      Select heparin formulation using renal function, timing and reversibility needs.

   Read the complete explanation

   UFH can be useful when rapid reversal or severe renal impairment is important. Normal kidneys and no imminent delivery make prolonged infusion less suitable than LMWH. Select heparin formulation using renal function, timing and reversibility needs.

3. C. Oral rivaroxaban at the standard VTE treatment dose (Why this does not fit)

   1. For which population is routine DOAC treatment well established?

      DOACs are useful for many nonpregnant adults with VTE.

   2. What does pregnancy change about that usual choice?

      Pregnancy lacks the necessary safety basis for this choice.

   3. How should this distinction guide a similar patient?

      Reassess usual oral-drug preferences during pregnancy.

   Read the complete explanation

   DOACs are useful for many nonpregnant adults with VTE. Pregnancy lacks the necessary safety basis for this choice. Reassess usual oral-drug preferences during pregnancy.

4. D. Weight-adjusted therapeutic low-molecular-weight heparin (Best answer)

   1. Does confirmed proximal DVT require prevention-dose or treatment-dose anticoagulation?

      Treatment-dose anticoagulation.

   2. Which drug class is generally preferred for pregnancy-associated VTE?

      Low-molecular-weight heparin.

   3. What supplied details favor LMWH over a reversible UFH infusion?

      Renal function is normal and delivery is not imminent.

   4. What makes the plan practical?

      The patient can self-inject, with no supplied heparin allergy or active bleeding.

   Read the complete explanation

   LMWH is preferred for most acute VTE treatment during pregnancy. Adequate renal function, no imminent delivery and ability to self-inject favor it. Combine pregnancy status with renal and peripartum considerations.

5. E. Prophylactic-dose low-molecular-weight heparin (Why this does not fit)

   1. What is prophylactic dosing intended to do?

      Prophylactic dosing is used to prevent events in selected risk settings.

   2. Does confirmed proximal DVT require prevention or treatment intensity?

      A proximal clot is already confirmed and requires therapeutic treatment.

   3. How should this distinction guide a similar patient?

      Distinguish prevention dosing from treatment of established VTE.

   Read the complete explanation

   Prophylactic dosing is used to prevent events in selected risk settings. A proximal clot is already confirmed and requires therapeutic treatment. Distinguish prevention dosing from treatment of established VTE.

Takeaway: Combine pregnancy status with renal and peripartum considerations.

Case sources: [6]

1. A. Transfer for catheter therapy before using any available reperfusion (Why this does not fit)

   1. When can catheter treatment be especially useful?

      Catheter therapy can be valuable in selected severe PE, especially when lysis is unsuitable.

   2. What cost would transfer impose when immediate lysis is suitable?

      A transfer delay is imposed despite severe shock and no supplied lysis contraindication.

   3. How should this distinction guide a similar patient?

      Balance intervention choice against the time needed to restore perfusion.

   Read the complete explanation

   Catheter therapy can be valuable in selected severe PE, especially when lysis is unsuitable. A transfer delay is imposed despite severe shock and no supplied lysis contraindication. Balance intervention choice against the time needed to restore perfusion.

2. B. Transfer for surgical embolectomy as the first reperfusion option (Why this does not fit)

   1. When can surgical embolectomy be the preferred rescue route?

      Surgery is an option when lysis is contraindicated or unsuccessful and expertise is available.

   2. Is a lysis contraindication or failed lysis supplied here?

      No such constraint is supplied, while transfer delays treatment of profound shock.

   3. How should this distinction guide a similar patient?

      Select rescue routes using contraindications, local capability and urgency.

   Read the complete explanation

   Surgery is an option when lysis is contraindicated or unsuccessful and expertise is available. No such constraint is supplied, while transfer delays treatment of profound shock. Select rescue routes using contraindications, local capability and urgency.

3. C. Continue anticoagulation alone and reassess in several hours (Why this does not fit)

   1. What can anticoagulation do immediately to clot propagation?

      Anticoagulation is foundational PE treatment and limits further clot propagation.

   2. Is that enough to address the current persistent shock without reperfusion assessment?

      Persistent shock requires consideration of urgent reperfusion beyond its slower indirect effects.

   3. How should this distinction guide a similar patient?

      Escalate according to perfusion failure rather than clot diagnosis alone.

   Read the complete explanation

   Anticoagulation is foundational PE treatment and limits further clot propagation. Persistent shock requires consideration of urgent reperfusion beyond its slower indirect effects. Escalate according to perfusion failure rather than clot diagnosis alone.

4. D. Administer systemic thrombolysis urgently with appropriate resuscitation (Best answer)

   1. What establishes cardiopulmonary failure beyond a positive CT?

      Persistent profound hypotension with cool extremities and rising lactate.

   2. Does the RV/LV pattern fit PE-associated obstructive shock?

      Yes. Acute RV dilation accompanies an underfilled LV.

   3. Is a major systemic-lysis contraindication supplied?

      No.

   4. Which reperfusion route can act without the transfer delay?

      Urgent systemic thrombolysis with appropriate resuscitation and monitoring.

   Read the complete explanation

   Systemic lysis is an established reperfusion option for PE with hemodynamic instability when bleeding risk permits. The patient is in shock, has no stated major contraindication and can receive treatment immediately. In PE shock, assess both bleeding risk and the fastest appropriate reperfusion route.

Takeaway: In PE shock, assess both bleeding risk and the fastest appropriate reperfusion route.

Case sources: [2] [3] [11]

1. A. Give full-dose systemic thrombolysis before consulting the procedural teams (Why this does not fit)

   1. What must be weighed before systemic thrombolysis?

      Systemic lysis is often considered in PE shock when bleeding risk permits.

   2. How does intracranial surgery five days ago change that balance?

      Very recent intracranial surgery creates a major intracranial bleeding hazard and alternatives are available now.

   3. How should this distinction guide a similar patient?

      Reperfusion urgency does not remove the need to assess the method's bleeding risk.

   Read the complete explanation

   Systemic lysis is often considered in PE shock when bleeding risk permits. Very recent intracranial surgery creates a major intracranial bleeding hazard and alternatives are available now. Reperfusion urgency does not remove the need to assess the method's bleeding risk.

2. B. Obtain urgent multidisciplinary assessment for surgical or catheter-based reperfusion (Best answer)

   1. Why is reperfusion assessment urgent?

      Shock and worsening perfusion persist despite initial resuscitation.

   2. What makes systemic lysis particularly hazardous?

      Intracranial surgery occurred only five days earlier.

   3. What relevant resources are available now?

      Surgical and catheter teams can assess immediately.

   4. What plan combines urgency with the bleeding constraint?

      Obtain urgent multidisciplinary selection of a surgical or catheter-based rescue strategy.

   Read the complete explanation

   Mechanical and surgical options can be considered when systemic lysis is contraindicated or hazardous. Severe ongoing shock and recent brain surgery make immediate expert selection appropriate. Match rescue technique to both circulatory failure and bleeding constraints.

3. C. Use anticoagulation alone while waiting for postoperative bleeding risk to fall (Why this does not fit)

   1. What can anticoagulation accomplish without immediate clot removal?

      Anticoagulation can limit clot propagation when tolerated.

   2. Does ongoing shock permit waiting for postoperative risk to decline?

      Persistent shock makes waiting for days of risk reduction inadequate without urgent rescue assessment.

   3. How should this distinction guide a similar patient?

      Address the immediate life-threatening physiology while selecting the least harmful feasible rescue.

   Read the complete explanation

   Anticoagulation can limit clot propagation when tolerated. Persistent shock makes waiting for days of risk reduction inadequate without urgent rescue assessment. Address the immediate life-threatening physiology while selecting the least harmful feasible rescue.

4. D. Use reduced-dose systemic thrombolysis as the default safer substitute (Why this does not fit)

   1. Does a lower lytic dose establish safety after recent brain surgery?

      No. Reducing the lytic dose does not establish acceptable intracranial safety after very recent brain surgery.

   2. Which major bleeding constraint remains despite dose reduction?

      Dose reduction does not establish acceptable intracranial safety five days after surgery.

   3. How should this distinction guide a similar patient?

      A smaller dose does not erase a major contraindication.

   Read the complete explanation

   Lower lytic exposure may be studied or considered in selected settings. Dose reduction does not establish acceptable intracranial safety five days after surgery. A smaller dose does not erase a major contraindication.

Takeaway: Match rescue technique to both circulatory failure and bleeding constraints.

Case sources: [2] [3] [11]

1. A. Add systemic thrombolysis to clear the central clot promptly (Why this does not fit)

   1. What physiological state can justify systemic lysis?

      Systemic lysis can restore perfusion in appropriately selected severe PE.

   2. Which such findings are absent despite the central clot?

      This patient has no supplied shock, RV injury or respiratory failure to justify its bleeding risk.

   3. How should this distinction guide a similar patient?

      Match reperfusion to physiological severity rather than a location label.

   Read the complete explanation

   Systemic lysis can restore perfusion in appropriately selected severe PE. This patient has no supplied shock, RV injury or respiratory failure to justify its bleeding risk. Match reperfusion to physiological severity rather than a location label.

2. B. Refer for urgent surgical embolectomy as the initial definitive treatment (Why this does not fit)

   1. When can surgical rescue offer a favorable balance?

      Surgery can provide reperfusion in selected high-risk situations.

   2. Does this patient have the physiological compromise that supports it?

      The supplied physiological assessment does not establish that level of urgency or benefit.

   3. How should this distinction guide a similar patient?

      Assess the patient's functional compromise before selecting surgical rescue.

   Read the complete explanation

   Surgery can provide reperfusion in selected high-risk situations. The supplied physiological assessment does not establish that level of urgency or benefit. Assess the patient's functional compromise before selecting surgical rescue.

3. C. Continue therapeutic anticoagulation and reassess clinical risk (Best answer)

   1. What does saddle describe on CT?

      Thrombus at the main pulmonary artery bifurcation.

   2. What physiological indication for immediate reperfusion is demonstrated?

      None is supplied: perfusion, troponin,RV size and breathing are reassuring.

   3. What remains the treatment foundation?

      Therapeutic anticoagulation.

   4. How should the central anatomy affect reassessment?

      It informs the clinical picture, but does not alone justify adding reperfusion's bleeding and procedural risks.

   Read the complete explanation

   Anticoagulation is the foundation for confirmed PE without a demonstrated need for immediate reperfusion. Reassuring perfusion and RV findings remain relevant despite the saddle anatomy. Use anatomy to understand the clot and physiology to guide escalation.

4. D. Arrange immediate catheter thrombectomy before further anticoagulation (Why this does not fit)

   1. Which presentations can justify urgent catheter removal?

      Catheter intervention can be considered in selected severe or deteriorating PE.

   2. Does the supplied trajectory demonstrate one of them?

      No current deterioration or cardiopulmonary failure is demonstrated.

   3. How should this distinction guide a similar patient?

      An invasive clot-removal procedure needs more than an impressive CT location.

   Read the complete explanation

   Catheter intervention can be considered in selected severe or deteriorating PE. No current deterioration or cardiopulmonary failure is demonstrated. An invasive clot-removal procedure needs more than an impressive CT location.

Takeaway: Use anatomy to understand the clot and physiology to guide escalation.

Case sources: [2] [3] [11]

1. A. The RV pattern is nonspecific; urgently evaluate both thromboembolic and ischemic explanations (Best answer)

   1. Can RV apical sparing with free-wall hypokinesis occur in PE?

      Yes, but the pattern is not specific to PE.

   2. Which supplied findings create an urgent competing concern?

      Inferior ST elevation and pressure-like chest pain raise concern for acute coronary ischemia.

   3. Can the PE differential postpone that coronary assessment?

      No. Urgent acute-coronary evaluation must proceed without that delay.

   4. What is the interpretive rule?

      Integrate overlapping RV findings with the full presentation rather than treating a named echo pattern as diagnostic proof.

   Read the complete explanation

   RV infarction and PE can produce overlapping regional RV findings. Inferior ST elevation with pressure-like pain requires urgent acute-coronary assessment; considering PE must not delay that care. Let discordant evidence broaden the urgent assessment instead of forcing a single-sign diagnosis.

2. B. The regional RV pattern establishes PE, so coronary evaluation can wait (Why this does not fit)

   1. Why can this RV pattern raise concern for PE?

      This echo pattern is associated with acute PE and RV strain.

   2. Which independent findings require urgent coronary assessment too?

      Inferior ischemic ECG findings and pressure-like pain provide a meaningful competing cause of RV dysfunction.

   3. How should this distinction guide a similar patient?

      A suggestive sign must be interpreted with the rest of the presentation.

   Read the complete explanation

   This echo pattern is associated with acute PE and RV strain. Inferior ischemic ECG findings and pressure-like pain provide a meaningful competing cause of RV dysfunction. A suggestive sign must be interpreted with the rest of the presentation.

3. C. The inferior ECG pattern excludes PE as a concurrent consideration (Why this does not fit)

   1. Why is inferior ST elevation clinically urgent?

      Inferior ST elevation warrants urgent assessment for coronary ischemia.

   2. Does it erase the separate thromboembolic evidence?

      It does not by itself negate the immobilization history and acute dyspnea.

   3. How should this distinction guide a similar patient?

      Evaluate a strong alternative without turning it into an unsupported exclusion rule.

   Read the complete explanation

   Inferior ST elevation warrants urgent assessment for coronary ischemia. It does not by itself negate the immobilization history and acute dyspnea. Evaluate a strong alternative without turning it into an unsupported exclusion rule.

4. D. The preserved RV apex makes clinically important RV disease unlikely (Why this does not fit)

   1. Can preserved function in one segment coexist with serious disease elsewhere?

      Regional preservation can coexist with substantial dysfunction elsewhere.

   2. What is abnormal in this RV and the overall presentation?

      The free wall is hypokinetic and symptoms plus ECG are abnormal.

   3. How should this distinction guide a similar patient?

      Preserved function in one segment does not neutralize dysfunction in another.

   Read the complete explanation

   Regional preservation can coexist with substantial dysfunction elsewhere. The free wall is hypokinetic and symptoms plus ECG are abnormal. Preserved function in one segment does not neutralize dysfunction in another.

Takeaway: Let discordant evidence broaden the urgent assessment instead of forcing a single-sign diagnosis.

Case sources: [3]

1. A. Perform coronary angiography based solely on the troponin rise (Why this does not fit)

   1. Should a troponin rise select coronary angiography by itself?

      No. The decision needs evidence supporting acute coronary ischemia, such as compatible symptoms and ischemic ECG changes.

   2. What does this complete presentation and ECG instead support investigating?

      The stated symptoms, strain pattern and probability favor a pulmonary evaluation; no diagnostic ST-elevation pattern is present.

   3. How should this distinction guide a similar patient?

      Interpret troponin as myocardial injury whose cause still requires clinical evidence.

   Read the complete explanation

   Coronary angiography is indicated when the complete presentation supports an acute coronary process. The stated symptoms, strain pattern and probability favor a pulmonary evaluation; no diagnostic ST-elevation pattern is present. Interpret troponin as myocardial injury whose cause still requires clinical evidence.

2. B. Obtain CTPA while assessing the patient for evolving RV compromise (Best answer)

   1. What can S1Q3T3 suggest?

      Right-heart strain in the appropriate clinical setting.

   2. Does that pattern or a mild troponin rise establish clot location?

      No. Both are supportive or consequence findings, not direct clot confirmation.

   3. Which independent assessment determines the test branch?

      The supplied likely-PE clinical probability.

   4. What imaging fits that branch and these constraints?

      CTPA, while assessing for evolving RV compromise.

   Read the complete explanation

   CTPA is appropriate in a likely-PE pathway when suitable. Symptoms and probability support imaging, while ECG and troponin alert the team to possible RV stress. Separate confirmation of PE from assessment of its physiological consequences.

3. C. Diagnose PE from the ECG and use echo only to grade severity (Why this does not fit)

   1. What can right-heart strain findings contribute to a PE assessment?

      Right-heart strain findings can increase concern for PE.

   2. Do they directly demonstrate a pulmonary clot?

      Neither S1Q3T3 nor a mild troponin rise directly establishes pulmonary arterial clot.

   3. How should this distinction guide a similar patient?

      Use supportive signs to guide urgency, then complete the diagnostic pathway.

   Read the complete explanation

   Right-heart strain findings can increase concern for PE. Neither S1Q3T3 nor a mild troponin rise directly establishes pulmonary arterial clot. Use supportive signs to guide urgency, then complete the diagnostic pathway.

4. D. Use D-dimer to decide whether CT is necessary (Why this does not fit)

   1. Where does D-dimer exclusion fit in a probability pathway?

      D-dimer can exclude PE in selected unlikely-probability pathways.

   2. Has this patient already entered a different branch?

      The supplied clinical assessment is already likely PE.

   3. How should this distinction guide a similar patient?

      Do not let a nonspecific ECG move a patient into the wrong diagnostic branch.

   Read the complete explanation

   D-dimer can exclude PE in selected unlikely-probability pathways. The supplied clinical assessment is already likely PE. Do not let a nonspecific ECG move a patient into the wrong diagnostic branch.

Takeaway: Separate confirmation of PE from assessment of its physiological consequences.

Case sources: [1] [3]

1. A. Reduced antithrombin activity impairs inhibition of thrombin (Why this does not fit)

   1. Which anticoagulant pathway does antithrombin regulate?

      Antithrombin inhibits thrombin and factor Xa as part of endogenous anticoagulant regulation.

   2. Is its measured activity the abnormal finding here?

      Antithrombin activity is normal, while the demonstrated abnormality concerns the activated-protein-C response.

   3. How should this distinction guide a similar patient?

      Match the assay abnormality to the affected anticoagulant pathway.

   Read the complete explanation

   Antithrombin deficiency can increase thrombotic risk. Antithrombin activity is normal, while the demonstrated abnormality concerns the activated-protein-C response. Match the assay abnormality to the affected anticoagulant pathway.

2. B. Reduced production of protein C leaves its plasma concentration low (Why this does not fit)

   1. What would protein C deficiency reduce?

      Protein C deficiency reduces its amount or functional activity, weakening anticoagulant regulation.

   2. What do the normal concentration and poor response to added activated protein C imply?

      Normal concentration with little response to added activated protein C points toward target resistance rather than inadequate protein C supply.

   3. How should this distinction guide a similar patient?

      Separate inhibitor deficiency from target resistance.

   Read the complete explanation

   Protein C deficiency can impair an anticoagulant pathway. Protein C concentration is normal and the assay adds activated protein C without restoring the expected response. Separate inhibitor deficiency from target resistance.

3. C. Increased prothrombin synthesis raises its circulating concentration (Why this does not fit)

   1. What does the prothrombin variant change?

      The prothrombin G20210A variant can increase prothrombin levels.

   2. Which functional response instead points to altered factor V regulation?

      The response to added activated protein C instead points to impaired target inactivation.

   3. How should this distinction guide a similar patient?

      Different inherited risks require different mechanistic explanations.

   Read the complete explanation

   The prothrombin G20210A variant can increase prothrombin levels. The response to added activated protein C instead points to impaired target inactivation. Different inherited risks require different mechanistic explanations.

4. D. Reduced cleavage of activated factor V prolongs its procoagulant activity (Best answer)

   1. Did the patient lack measurable protein C?

      No. Its concentration is normal.

   2. What happened when activated protein C was added?

      Clotting time prolonged much less than expected.

   3. What does that suggest about the target of activated protein C?

      Resistance to its anticoagulant effect rather than simply an inadequate supply.

   4. What factor V change explains this pattern?

      Reduced cleavage of activated factor V allows its procoagulant activity to persist.

   Read the complete explanation

   Activated protein C normally helps inactivate factor Va. Added activated protein C has little effect because the variant factor V is relatively resistant to cleavage. A normal inhibitor concentration does not guarantee that its target responds normally.

Takeaway: A normal inhibitor concentration does not guarantee that its target responds normally.

Case sources: [5]

1. A. Dabigatran after adequate heparin lead-in (Why this does not fit)

   1. Which treatment phase precedes dabigatran in an acute VTE regimen?

      Dabigatran can treat selected VTE after initial parenteral therapy.

   2. Would fulfilling that sequence resolve the APS-specific drug concern?

      Completing a lead-in does not remove the APS-related concern about oral-agent choice.

   3. How should this distinction guide a similar patient?

      A correct initiation sequence does not establish suitability for every thrombophilia.

   Read the complete explanation

   Dabigatran can treat selected VTE after initial parenteral therapy. Completing a lead-in does not remove the APS-related concern about oral-agent choice. A correct initiation sequence does not establish suitability for every thrombophilia.

2. B. Warfarin with an INR target of 2 to 3 (Best answer)

   1. Is this merely a transient positive antibody result?

      No. Triple positivity persists across tests 14 weeks apart.

   2. What clinical events make the antibody pattern relevant?

      Recurrent thrombosis and pregnancy morbidity.

   3. Which long-term oral-drug preference changes in high-risk thrombotic APS?

      A vitamin K antagonist is preferred over routine DOAC use.

   4. Which supplied strategy fits the venous setting?

      Warfarin targetingINR2 to 3, with feasible monitoring.

   Read the complete explanation

   A vitamin K antagonist is preferred for this high-risk thrombotic APS profile. Persistent triple positivity, recurrent venous events and feasible INR monitoring support this choice. Persistent antibody pattern and clinical events together change the long-term drug plan.

3. C. Apixaban at a therapeutic VTE dose (Why this does not fit)

   1. When is apixaban a usual VTE option?

      Apixaban is suitable for many patients with VTE.

   2. Which persistent antibody pattern changes that general preference?

      The supplied persistent triple-positive APS favors a vitamin K antagonist rather than extrapolating routine DOAC use.

   3. How should this distinction guide a similar patient?

      Check disease-specific exceptions before choosing a familiar oral agent.

   Read the complete explanation

   Apixaban is suitable for many patients with VTE. The supplied persistent triple-positive APS favors a vitamin K antagonist rather than extrapolating routine DOAC use. Check disease-specific exceptions before choosing a familiar oral agent.

4. D. Rivaroxaban at a therapeutic VTE dose (Why this does not fit)

   1. Why is rivaroxaban attractive in many VTE settings?

      Rivaroxaban is convenient and effective for many VTE populations.

   2. What trial-relevant disease profile creates an exception here?

      High-risk triple-positive APS is an important exception with unfavorable trial evidence.

   3. How should this distinction guide a similar patient?

      General DOAC preference does not apply uniformly to thrombotic APS.

   Read the complete explanation

   Rivaroxaban is convenient and effective for many VTE populations. High-risk triple-positive APS is an important exception with unfavorable trial evidence. General DOAC preference does not apply uniformly to thrombotic APS.

Takeaway: Persistent antibody pattern and clinical events together change the long-term drug plan.

Case sources: [3] [9]

1. A. Continue heparin until ultrasound shows complete clot disappearance (Why this does not fit)

   1. How do anticoagulants relate to eventual clot resolution?

      Anticoagulants prevent propagation and recurrence while endogenous processes clear clot.

   2. Is complete ultrasound normalization the bridge endpoint?

      Imaging resolution can lag far beyond the required initiation overlap.

   3. How should this distinction guide a similar patient?

      Use validated treatment milestones rather than waiting for an anatomic endpoint.

   Read the complete explanation

   Anticoagulants prevent propagation and recurrence while endogenous processes clear clot. Imaging resolution can lag far beyond the required initiation overlap. Use validated treatment milestones rather than waiting for an anatomic endpoint.

2. B. Continue overlap for at least five days and until INR is therapeutic for at least 24 hours (Best answer)

   1. How long has the heparin–warfarin overlap lasted?

      Only two days.

   2. Why can INR rise before full antithrombotic effect develops?

      Shorter-lived factors fall before longer-lived procoagulant factors are adequately reduced.

   3. What minimum overlap duration remains necessary?

      At least five days.

   4. What additional INR condition is required before stopping heparin?

      A therapeutic INR for at least 24 hours, alongside that minimum duration.

   Read the complete explanation

   Warfarin takes time to reduce longer-lived procoagulant factors adequately. An early INR of 2.2 does not replace the minimum treatment overlap. Interpret the INR in relation to time since warfarin initiation.

3. C. Stop heparin now because the INR has entered range (Why this does not fit)

   1. Which stopping criterion does an INR in range satisfy?

      A therapeutic INR is part of the criterion for ending overlap.

   2. Which separate criterion remains unmet on day 2?

      Only two days have elapsed, before the minimum overlap needed for acute VTE treatment.

   3. How should this distinction guide a similar patient?

      Satisfy duration and INR criteria together.

   Read the complete explanation

   A therapeutic INR is part of the criterion for ending overlap. Only two days have elapsed, before the minimum overlap needed for acute VTE treatment. Satisfy duration and INR criteria together.

4. D. Stop heparin after one more therapeutic INR tomorrow (Why this does not fit)

   1. What does another therapeutic INR demonstrate?

      Repeated INR confirmation adds evidence of a stable measured response.

   2. Would a day 3 result meet the minimum overlap duration?

      Day 3 would still fall short of the minimum five-day overlap.

   3. How should this distinction guide a similar patient?

      Repetition of one criterion does not satisfy a separate timing criterion.

   Read the complete explanation

   Repeated INR confirmation adds evidence of a stable measured response. Day 3 would still fall short of the minimum five-day overlap. Repetition of one criterion does not satisfy a separate timing criterion.

Takeaway: Interpret the INR in relation to time since warfarin initiation.

Case sources: [4]

1. A. Reduce anticoagulation to prophylactic dosing as definitive VTE treatment (Why this does not fit)

   1. Which indications use prophylactic rather than therapeutic dosing?

      Lower dosing is used for prevention and some later extended-treatment contexts.

   2. Would that dose provide established acute-PE treatment during this bleed?

      It is not an established substitute for therapeutic acute VTE treatment during uncontrolled major bleeding.

   3. How should this distinction guide a similar patient?

      A reduced dose must still match the indication and current bleeding safety.

   Read the complete explanation

   Lower dosing is used for prevention and some later extended-treatment contexts. It is not an established substitute for therapeutic acute VTE treatment during uncontrolled major bleeding. A reduced dose must still match the indication and current bleeding safety.

2. B. Use catheter-delivered thrombolysis to avoid systemic bleeding risk (Why this does not fit)

   1. What bleeding mechanism remains with catheter-delivered lysis?

      Local delivery may reduce systemic exposure but still introduces a fibrinolytic bleeding hazard.

   2. Does active major GI bleeding cease to matter with local delivery?

      Active major GI bleeding remains a major constraint.

   3. How should this distinction guide a similar patient?

      A different delivery route does not remove the drug's fundamental bleeding risk.

   Read the complete explanation

   Local delivery may reduce systemic exposure but still introduces a fibrinolytic bleeding hazard. Active major GI bleeding remains a major constraint. A different delivery route does not remove the drug's fundamental bleeding risk.

3. C. Insert a permanent filter and discontinue future anticoagulation plans (Why this does not fit)

   1. When might a persistent contraindication justify a long-term filter?

      Long-term filters may be unavoidable in selected persistent contraindications.

   2. Is the stated contraindication expected to persist?

      The supplied contraindication is expected to resolve.

   3. How should this distinction guide a similar patient?

      A temporary barrier to treatment does not justify abandoning reassessment.

   Read the complete explanation

   Long-term filters may be unavoidable in selected persistent contraindications. The supplied contraindication is expected to resolve. A temporary barrier to treatment does not justify abandoning reassessment.

4. D. Assess a retrievable IVC filter with a plan to restart anticoagulation and remove it (Best answer)

   1. What currently prevents therapeutic anticoagulation?

      Ongoing major GI bleeding requiring transfusion.

   2. Is that contraindication expected to be permanent?

      No. It is expected to resolve after bleeding control.

   3. What temporary mechanical option can be assessed?

      A retrievableIVC filter in this acute PE/proximal DVT setting.

   4. What must be planned at the same time?

      Reassess for anticoagulation restart and remove the filter when it is no longer needed.

   Read the complete explanation

   A filter may be considered when acute VTE coexists with a contraindication to anticoagulation. The active bleed creates that temporary gap, so restart and retrieval planning are essential. Treat filter use as a time-limited exception with follow-up ownership.

5. E. Continue therapeutic anticoagulation at the same dose during active bleeding (Why this does not fit)

   1. Why is therapeutic anticoagulation central to acute VTE?

      Therapeutic anticoagulation limits clot propagation and reduces recurrent thromboembolism.

   2. What new bleeding event changes its immediate safety?

      Ongoing major bleeding requiring transfusion is a current contraindication.

   3. How should this distinction guide a similar patient?

      Reassess treatment immediately when major bleeding changes the risk balance.

   Read the complete explanation

   Anticoagulation is the central treatment for most acute VTE. Ongoing major bleeding requiring transfusion is a current contraindication. Reassess treatment immediately when major bleeding changes the risk balance.

Takeaway: Treat filter use as a time-limited exception with follow-up ownership.

Case sources: [4]

1. A. Order routine inherited-thrombophilia testing before deciding whether to stop (Why this does not fit)

   1. When can a hereditary panel improve a management decision?

      Testing can matter in selected scenarios where results change management.

   2. Does this first surgery-provoked event routinely require it?

      A first surgery-provoked event does not routinely require a panel to decide duration.

   3. How should this distinction guide a similar patient?

      Ask how a test would change the plan before ordering it.

   Read the complete explanation

   Testing can matter in selected scenarios where results change management. A first surgery-provoked event does not routinely require a panel to decide duration. Ask how a test would change the plan before ordering it.

2. B. Consider stopping anticoagulation after reviewing recurrence and bleeding risks (Best answer)

   1. Was the event unprovoked or linked to a major transient factor?

      It followed knee replacement.

   2. Does that provoking factor still persist?

      No. Mobility has returned and the surgical trigger has resolved.

   3. Has an adequate primary course been completed?

      Yes. Three months are complete.

   4. What duration discussion follows with no continuing indication?

      Consider stopping after reviewing recurrence risk, bleeding risk and preferences.

   Read the complete explanation

   A first event provoked by a resolved major transient factor often needs a finite course. Three months are complete and the supplied ongoing-risk assessment is reassuring. Reassess duration using the trigger, persistence of risk and patient circumstances.

3. C. Extend treatment until D-dimer is repeatedly undetectable (Why this does not fit)

   1. What valid roles can D-dimer have?

      D-dimer can have diagnostic and selected prognostic roles.

   2. Is repeated undetectability a required treatment endpoint here?

      This plan substitutes an unrequired laboratory endpoint for the clinical duration assessment.

   3. How should this distinction guide a similar patient?

      Do not create an indefinite course from an assay without a validated decision role.

   Read the complete explanation

   D-dimer can have diagnostic and selected prognostic roles. This plan substitutes an unrequired laboratory endpoint for the clinical duration assessment. Do not create an indefinite course from an assay without a validated decision role.

4. D. Continue full-dose anticoagulation indefinitely because the clot was proximal (Why this does not fit)

   1. What does proximal location establish about initial treatment?

      Proximal location warrants adequate initial treatment.

   2. Does it independently establish a lifelong indication after a resolved surgical trigger?

      Location alone does not establish indefinite benefit after a resolved major surgical trigger.

   3. How should this distinction guide a similar patient?

      Separate the need for acute treatment from the decision about extended prevention.

   Read the complete explanation

   Proximal location warrants adequate initial treatment. Location alone does not establish indefinite benefit after a resolved major surgical trigger. Separate the need for acute treatment from the decision about extended prevention.

5. E. Continue until follow-up ultrasound shows a completely normal vein (Why this does not fit)

   1. Can venous abnormalities persist after adequate treatment?

      Residual venous abnormalities may persist after an adequately treated DVT.

   2. Must the vein become entirely normal before a finite course can end?

      Anatomical normalization is not the routine endpoint for this finite-course decision.

   3. How should this distinction guide a similar patient?

      Duration depends on recurrence prevention, not mandatory disappearance of every imaging abnormality.

   Read the complete explanation

   Residual venous abnormalities may persist after an adequately treated DVT. Anatomical normalization is not the routine endpoint for this finite-course decision. Duration depends on recurrence prevention, not mandatory disappearance of every imaging abnormality.

Takeaway: Reassess duration using the trigger, persistence of risk and patient circumstances.

Case sources: [1] [4] [5]

1. A. Use anticoagulation only during future travel or immobilization (Why this does not fit)

   1. When does episodic prophylaxis match the pattern of risk?

      Episodic prophylaxis can be relevant to discrete high-risk exposures.

   2. Does the supplied history limit the problem to future travel or immobilization?

      The stem does not link either event solely to travel or immobilization; that narrow schedule would not address the supplied recurrence history.

   3. How should this distinction guide a similar patient?

      Match prevention duration to whether the recurrence risk is episodic or persistent.

   Read the complete explanation

   Episodic prophylaxis can be relevant to discrete high-risk exposures. The stem does not link either event solely to travel or immobilization; that narrow schedule would not address the supplied recurrence history. Match prevention duration to whether the recurrence risk is episodic or persistent.

2. B. Stop anticoagulation after the completed primary-treatment course (Why this does not fit)

   1. What circumstances can favor a finite course?

      Finite therapy may be appropriate after some resolved transient triggers or when bleeding risk dominates.

   2. Does the absence of a major transient trigger support a low-recurrence assumption after two events?

      This is recurrent PE without a major transient trigger, with low stated bleeding risk.

   3. How should this distinction guide a similar patient?

      Repeated events without a major transient trigger shift the balance toward continued prevention.

   Read the complete explanation

   Finite therapy may be appropriate after some resolved transient triggers or when bleeding risk dominates. This is recurrent PE without a major transient trigger, with low stated bleeding risk. Repeated events without a major transient trigger shift the balance toward continued prevention.

3. C. Replace anticoagulation with aspirin for secondary prevention (Why this does not fit)

   1. How does aspirin compare with anticoagulation for VTE prevention?

      Aspirin is less effective than anticoagulation for secondary prevention of VTE in a patient able to receive anticoagulation.

   2. Is it the stronger option for this treatment-tolerant patient?

      It is less effective than anticoagulation for recurrent VTE prevention in a suitable patient.

   3. How should this distinction guide a similar patient?

      Do not equate a weaker preventive option with therapeutic anticoagulation.

   Read the complete explanation

   Aspirin may reduce some recurrence risk when anticoagulation is not used. It is less effective than anticoagulation for recurrent VTE prevention in a suitable patient. Do not equate a weaker preventive option with therapeutic anticoagulation.

4. D. Continue extended anticoagulation with periodic reassessment (Best answer)

   1. What distinguishes this from a first event after a resolved major transient trigger?

      It is a second PE with no major transient trigger identified for either event.

   2. Does the supplied history justify limiting prevention to future travel or immobilization?

      No. That narrow schedule would not address this recurrence history.

   3. What supplied factor favors continued treatment's balance?

      Bleeding risk is low and anticoagulation is tolerated.

   4. What strategy follows?

      Extended anticoagulation with periodic reassessment rather than an automatic finite stop.

   Read the complete explanation

   Extended therapy reduces recurrent VTE while treatment continues. Recurrent events without a major transient trigger and low bleeding risk favor ongoing prevention. Continued treatment still requires regular review of bleeding, renal function and preferences.

Takeaway: Continued treatment still requires regular review of bleeding, renal function and preferences.

Case sources: [4] [11]

1. A. Apixaban (Why this does not fit)

   1. Which anticoagulant class does apixaban belong to?

      Apixaban is an oral factor Xa inhibitor used for VTE treatment in suitable patients, including selected patients with cancer.

   2. Does this patient's regimen remove or add an interaction concern?

      This regimen has a relevant Xa-inhibitor interaction, and the gastric lesion adds a bleeding concern.

   3. How should this distinction guide a similar patient?

      A drug's general evidence does not remove patient-specific constraints.

   Read the complete explanation

   Apixaban is an option for many patients with cancer-associated VTE. This regimen has a relevant Xa-inhibitor interaction, and the gastric lesion adds a bleeding concern. A drug's general evidence does not remove patient-specific constraints.

2. B. Rivaroxaban (Why this does not fit)

   1. Which patient factors matter before choosing rivaroxaban in cancer?

      Bleeding risk, kidney function and drug interactions are important selection factors before using rivaroxaban for cancer-associated VTE.

   2. Which mucosal and interaction findings reduce its suitability here?

      A friable luminal GI lesion plus an important oral-Xa interaction makes it less suitable here.

   3. How should this distinction guide a similar patient?

      Choose the agent after checking both tumor bleeding risk and drug interactions.

   Read the complete explanation

   Rivaroxaban can treat cancer-associated VTE in selected patients. A friable luminal GI lesion plus an important oral-Xa interaction makes it less suitable here. Choose the agent after checking both tumor bleeding risk and drug interactions.

3. C. Dabigatran after a heparin lead-in (Why this does not fit)

   1. What initiation sequence is used with dabigatran?

      Dabigatran treats selected VTE after parenteral initiation.

   2. Does that sequence resolve the supplied cancer and luminal GI concerns?

      The cancer-associated evidence and active luminal-GI concerns favor LMWH in this presentation.

   3. How should this distinction guide a similar patient?

      A valid initiation sequence does not make an oral agent the best choice for every cancer patient.

   Read the complete explanation

   Dabigatran treats selected VTE after parenteral initiation. The cancer-associated evidence and active luminal-GI concerns favor LMWH in this presentation. A valid initiation sequence does not make an oral agent the best choice for every cancer patient.

4. D. Warfarin (Why this does not fit)

   1. How is warfarin treatment monitored and adjusted?

      Warfarin treatment is adjusted using serial INR measurements.

   2. Why does LMWH fit this initial cancer-associated setting better?

      LMWH is generally favored over a vitamin K antagonist for this initial cancer-associated setting and avoids the supplied oral-agent problems.

   3. How should this distinction guide a similar patient?

      Compare suitability in the actual cancer-treatment context.

   Read the complete explanation

   Warfarin can be used when patient circumstances favor a monitored vitamin K antagonist. LMWH is generally favored over a vitamin K antagonist for this initial cancer-associated setting and avoids the supplied oral-agent problems. Compare suitability in the actual cancer-treatment context.

5. E. Low-molecular-weight heparin (Best answer)

   1. What tumor feature increases bleeding concern?

      A friable luminal gastric lesion with recent occult bleeding.

   2. What additional constraint affects the contemplated oral Xa inhibitors?

      Important interactions with the cancer regimen.

   3. What supplied organ and laboratory findings permit LMWH?

      Kidney function and platelets are suitable.

   4. Which initial agent best fits those combined constraints?

      Therapeutic LMWH, with continued review as cancer treatment and bleeding risk change.

   Read the complete explanation

   LMWH is useful when mucosal bleeding concerns or interactions complicate oral treatment. Renal function and platelets permit it, while the supplied oral-agent constraints are important. Reassess the drug as cancer treatment and bleeding risk change.

Takeaway: Reassess the drug as cancer treatment and bleeding risk change.

Case sources: [10]

1. A. Assess clinical risk and contraceptive options without routine testing (Best answer)

   1. How strong is the supplied family signal for a known inherited defect?

      It is limited: one elderly second-degree relative had a surgery-provoked event.

   2. Is a specific familial thrombophilia known?

      No.

   3. Does this create a routine pre-contraception screening indication?

      No. It remains a setting where broad routine screening is not recommended.

   4. What counseling still matters?

      Assess clinical risk and discuss contraceptive options and estrogen-related risk without promising that testing would guarantee safety.

   Read the complete explanation

   General-population screening before combined oral contraception is not recommended. The supplied personal and family history does not create a specific high-risk testing indication. Discuss estrogen-related risk even when hereditary testing is not indicated.

2. B. Order antithrombin activity first and expand testing if abnormal (Why this does not fit)

   1. When can selective antithrombin testing change counseling?

      Selective testing for a known high-risk familial defect can change counseling.

   2. Is a known familial deficiency or strong relevant history supplied?

      There is no known antithrombin deficiency or strong unprovoked family pattern here.

   3. How should this distinction guide a similar patient?

      Choose a targeted test for a supported familial question, not a nonspecific history.

   Read the complete explanation

   Selective testing for a known high-risk familial defect can change counseling. There is no known antithrombin deficiency or strong unprovoked family pattern here. Choose a targeted test for a supported familial question, not a nonspecific history.

3. C. Order factor V Leiden testing alone before prescribing (Why this does not fit)

   1. Would known low-risk familial factor V Leiden alone routinely justify pre-contraception testing?

      Even known familial low-risk (heterozygous) factor V Leiden alone does not routinely justify testing before combined oral contraception under ASH guidance.

   2. Has a familial factor V variant been identified here?

      No familial variant is known here, and the weak provoked family history gives no additional indication for this test.

   3. How should this distinction guide a similar patient?

      Distinguish low-risk factor V Leiden from high-risk familial deficiencies when judging whether testing changes contraceptive counseling.

   Read the complete explanation

   Even known familial low-risk (heterozygous) factor V Leiden alone does not routinely justify testing before combined oral contraception under ASH guidance. No familial variant is known here, and the weak provoked family history gives no additional indication for this test. Distinguish low-risk factor V Leiden from high-risk familial deficiencies when judging whether testing changes contraceptive counseling.

4. D. Order a broad hereditary thrombophilia panel before prescribing (Why this does not fit)

   1. What management consequence should be specified before ordering a thrombophilia panel?

      Specify how a positive or negative result would change contraceptive selection or other care; obtaining a result alone is not a sufficient purpose.

   2. Does this weak provoked family history create that screening indication?

      This weak provoked family history does not establish an indication for general screening.

   3. How should this distinction guide a similar patient?

      Evaluate the relationship, age and trigger behind a reported family clot.

   Read the complete explanation

   A panel can be useful when a result has a defined management consequence in selected situations. This weak provoked family history does not establish an indication for general screening. Evaluate the relationship, age and trigger behind a reported family clot.

Takeaway: Discuss estrogen-related risk even when hereditary testing is not indicated.

Case sources: [5]

1. A. Stop anticoagulation immediately to obtain an uncontaminated repeat panel (Why this does not fit)

   1. How could drug timing be addressed in a planned testing strategy?

      Removing a confounder may be part of a planned specialist testing strategy.

   2. Would abrupt interruption of acute treatment be justified solely by this panel?

      Abrupt interruption during VTE treatment creates risk and is not justified solely by these results.

   3. How should this distinction guide a similar patient?

      Plan testing around safe care rather than interrupting effective treatment for an assay.

   Read the complete explanation

   Removing a confounder may be part of a planned specialist testing strategy. Abrupt interruption during VTE treatment creates risk and is not justified solely by these results. Plan testing around safe care rather than interrupting effective treatment for an assay.

2. B. Attribute the findings to factor V Leiden despite the prior normal result (Why this does not fit)

   1. What mechanism defines factor V Leiden?

      Factor V Leiden causes resistance of factor V to activated protein C.

   2. Does that explain the timing of the low protein C and protein S levels?

      It does not explain this treatment-timed reduction in measured protein C and S activities.

   3. How should this distinction guide a similar patient?

      Distinguish abnormal inhibitor levels from resistance of the inhibitor's target.

   Read the complete explanation

   Factor V Leiden causes resistance of factor V to activated protein C. It does not explain this treatment-timed reduction in measured protein C and S activities. Distinguish abnormal inhibitor levels from resistance of the inhibitor's target.

3. C. Treat the results as warfarin-confounded and reassess testing only if it would change care (Best answer)

   1. When were the low protein C andS values measured?

      During therapeutic warfarin treatment.

   2. What does warfarin do to these vitamin K-dependent proteins?

      It lowers their measured activity.

   3. What does the earlier normal protein C add?

      It supports caution against diagnosing an inherited deficiency from the treatment-timed result.

   4. What is the appropriate testing plan?

      Revisit testing only if it changes care and can be arranged safely, without abrupt interruption solely for the panel.

   Read the complete explanation

   Warfarin reduces vitamin K-dependent protein C and protein S. The low values follow treatment, while pretreatment protein C was normal. Interpret functional thrombophilia assays using timing, drug exposure and management relevance.

4. D. Diagnose combined inherited protein C and protein S deficiency now (Why this does not fit)

   1. What is needed before assigning an inherited functional deficiency?

      Inherited deficiencies require valid interpretation of appropriate assays.

   2. Were these samples obtained under interpretable conditions?

      Both results were obtained during a drug exposure that lowers these proteins.

   3. How should this distinction guide a similar patient?

      Exclude acquired and treatment effects before assigning an inherited label.

   Read the complete explanation

   Inherited deficiencies require valid interpretation of appropriate assays. Both results were obtained during a drug exposure that lowers these proteins. Exclude acquired and treatment effects before assigning an inherited label.

Takeaway: Interpret functional thrombophilia assays using timing, drug exposure and management relevance.

Case sources: [5]

1. A. Start an oral anticoagulant and arrange routine outpatient follow-up (Why this does not fit)

   1. Which DVT presentations may be managed outside hospital?

      Oral anticoagulation is appropriate for many uncomplicated stable DVT cases.

   2. Do cyanosis, a cool foot and sensory change fit that group?

      Cyanosis, threatened perfusion and sensory change indicate a limb emergency.

   3. How should this distinction guide a similar patient?

      Escalate the setting of care when venous thrombosis threatens tissue viability.

   Read the complete explanation

   Oral anticoagulation is appropriate for many uncomplicated stable DVT cases. Cyanosis, threatened perfusion and sensory change indicate a limb emergency. Escalate the setting of care when venous thrombosis threatens tissue viability.

2. B. Perform arterial embolectomy based on the faint pulse alone (Why this does not fit)

   1. What lesion does arterial embolectomy remove?

      Arterial embolectomy removes an obstructing arterial embolus to restore arterial inflow.

   2. Is arterial inflow obstruction the demonstrated primary lesion?

      The demonstrated lesion is massive venous outflow obstruction with cyanotic swelling.

   3. How should this distinction guide a similar patient?

      Identify whether inflow or outflow is the primary obstruction before selecting a procedure.

   Read the complete explanation

   Arterial occlusion can cause a cool pulseless limb. The demonstrated lesion is massive venous outflow obstruction with cyanotic swelling. Identify whether inflow or outflow is the primary obstruction before selecting a procedure.

3. C. Use compression and elevation as the sole initial treatment for several hours (Why this does not fit)

   1. What can elevation and compression provide?

      Supportive measures can reduce symptoms in selected venous disease.

   2. Would symptom support alone address the threatened perfusion?

      They do not address a rapidly threatened limb from extensive acute obstruction.

   3. How should this distinction guide a similar patient?

      Supportive care must not delay time-critical specialist treatment.

   Read the complete explanation

   Supportive measures can reduce symptoms in selected venous disease. They do not address a rapidly threatened limb from extensive acute obstruction. Supportive care must not delay time-critical specialist treatment.

4. D. Begin urgent anticoagulation assessment and obtain immediate vascular/interventional review (Best answer)

   1. What vascular lesion is demonstrated?

      Extensive acute iliofemoral DVT.

   2. What findings show more than uncomplicated venous swelling?

      Cyanosis, a cool foot, faint pulses and emerging sensory change indicate threatened perfusion.

   3. What does that imply about the setting and urgency of care?

      Immediate vascular or interventional assessment is needed.

   4. What treatment direction accompanies that review?

      Urgent anticoagulation assessment and consideration of thrombus removal for the threatened limb.

   Read the complete explanation

   Limb-threatening iliofemoral venous obstruction may require urgent thrombus-removal assessment in addition to anticoagulation. The blue, painful swollen leg with impaired perfusion fits this high-risk presentation. Treat the threatened limb, not only the diagnosis of DVT.

Takeaway: Treat the threatened limb, not only the diagnosis of DVT.

Case sources: [4]

1. A. Right-heart catheterization as the screening test for obstruction (Why this does not fit)

   1. What does right-heart catheterization directly measure?

      Catheterization confirms pulmonary hemodynamics and can characterize pulmonary hypertension.

   2. Does pressure confirmation identify regional thromboembolic perfusion defects?

      Pressure measurements alone do not screen regional thromboembolic perfusion defects.

   3. How should this distinction guide a similar patient?

      Distinguish hemodynamic confirmation from identifying a thromboembolic cause.

   Read the complete explanation

   Catheterization confirms pulmonary hemodynamics and can characterize pulmonary hypertension. Pressure measurements alone do not screen regional thromboembolic perfusion defects. Distinguish hemodynamic confirmation from identifying a thromboembolic cause.

2. B. Ventilation-perfusion scintigraphy (Best answer)

   1. What makes this a chronic post-PE question?

      Symptoms persist four months after the event, with possible pulmonary hypertension.

   2. Did the CT establish that no chronic perfusion problem exists?

      No. It found no new acute embolus.

   3. Which test screens for regional perfusion obstruction?

      Ventilation-perfusion scintigraphy.

   4. What distinct role can catheterization have afterward?

      Confirming and characterizing pulmonary hemodynamics when the diagnostic pathway calls for it.

   Read the complete explanation

   V/Q imaging is useful for screening suspected chronic thromboembolic disease. Persistent symptoms and pulmonary-pressure findings justify examining residual perfusion despite no new acute clot on CT. Use a chronic-disease pathway when post-PE recovery remains incomplete.

3. C. Repeat routine CTPA with the same acute-PE protocol (Why this does not fit)

   1. What vascular information does CT provide?

      CT directly visualizes pulmonary arterial anatomy and may show chronic changes.

   2. What screening question remains after acute recurrence has been assessed?

      The present question is a sensitive screen for persistent perfusion obstruction after acute recurrence has been assessed.

   3. How should this distinction guide a similar patient?

      Choose the modality for the unresolved question rather than repeat the prior acute study.

   Read the complete explanation

   CT directly visualizes pulmonary arterial anatomy and may show chronic changes. The present question is a sensitive screen for persistent perfusion obstruction after acute recurrence has been assessed. Choose the modality for the unresolved question rather than repeat the prior acute study.

4. D. Cardiac magnetic resonance measurement of RV volumes (Why this does not fit)

   1. What can cardiac MRI measure accurately?

      Cardiac MRI can assess RV size and function accurately.

   2. Does RV size alone answer the pulmonary-obstruction question?

      It does not directly answer the regional pulmonary perfusion-screening question asked here.

   3. How should this distinction guide a similar patient?

      Select a test for cause as well as for cardiac consequences.

   Read the complete explanation

   Cardiac MRI can assess RV size and function accurately. It does not directly answer the regional pulmonary perfusion-screening question asked here. Select a test for cause as well as for cardiac consequences.

5. E. Exercise spirometry as the initial obstruction screen (Why this does not fit)

   1. What alternative cause can spirometry help assess?

      Spirometry can identify airflow obstruction as an alternative contributor to breathlessness.

   2. Does an airway test screen the vascular mechanism under investigation?

      The specific unresolved concern is chronic pulmonary vascular obstruction with pulmonary hypertension.

   3. How should this distinction guide a similar patient?

      Evaluate alternative causes without substituting an airway test for a vascular question.

   Read the complete explanation

   Pulmonary function testing can help evaluate alternative causes of breathlessness. The specific unresolved concern is chronic pulmonary vascular obstruction with pulmonary hypertension. Evaluate alternative causes without substituting an airway test for a vascular question.

Takeaway: Use a chronic-disease pathway when post-PE recovery remains incomplete.

Case sources: [3] [11]

1. A. Category B: symptomatic PE with low clinical severity (Why this does not fit)

   1. What physiological profile belongs in category B?

      CategoryB covers symptomatic presentations with a low clinical-severity profile.

   2. Do these worsening organ findings fit low clinical severity?

      Worsening perfusion and increasing oxygen needs are incompatible with that low-risk state.

   3. How should this distinction guide a similar patient?

      Use the whole physiological profile when assigning severity.

   Read the complete explanation

   CategoryB covers symptomatic presentations with a low clinical-severity profile. Worsening perfusion and increasing oxygen needs are incompatible with that low-risk state. Use the whole physiological profile when assigning severity.

2. B. Category C: symptomatic PE with elevated severity but stable cardiopulmonary function (Why this does not fit)

   1. What can category C include while function remains stable?

      CategoryC includes elevated severity scores and may include RV dysfunction or biomarkers.

   2. What new organ-level findings show progression beyond stable injury markers?

      This patient is progressing beyond stable injury markers to hypoperfusion and worsening respiration.

   3. How should this distinction guide a similar patient?

      Distinguish a risk marker from an evolving organ-failure trajectory.

   Read the complete explanation

   CategoryC includes elevated severity scores and may include RV dysfunction or biomarkers. This patient is progressing beyond stable injury markers to hypoperfusion and worsening respiration. Distinguish a risk marker from an evolving organ-failure trajectory.

3. C. Category D: incipient cardiopulmonary failure (Best answer)

   1. Which findings show hypoperfusion despite blood pressure 112/70?

      Rising lactate, cool extremities and oliguria.

   2. What respiratory trend adds concern?

      Increasing oxygen requirements.

   3. Is this only stable RV injury, or a progression toward failure?

      The evolving organ-perfusion and respiratory abnormalities indicate incipient failure.

   4. Which 2026 category fits before persistent hypotension is established?

      CategoryD, prompting urgent escalation assessment.

   Read the complete explanation

   The framework recognizes impending failure from evolving perfusion or respiratory abnormalities. Rising lactate, oliguria, cool limbs and increasing oxygen needs support this state despite preserved pressure. Escalate according to perfusion and support trajectory as well as blood pressure.

4. D. Category E: cardiopulmonary failure with persistent hypotension (Why this does not fit)

   1. What hemodynamic finding characterizes the advanced category E state?

      Persistent hypotension, refractory shock or arrest characterizes the more advanced failure category.

   2. Is persistent hypotension supplied at this assessment?

      Systolic pressure remains 112, while the evidence supports failure developing before persistent hypotension.

   3. How should this distinction guide a similar patient?

      Recognize an earlier severe state rather than wait for a later defining pressure change.

   Read the complete explanation

   Persistent hypotension, refractory shock or arrest characterizes the more advanced failure category. Systolic pressure remains 112, while the evidence supports failure developing before persistent hypotension. Recognize an earlier severe state rather than wait for a later defining pressure change.

Takeaway: Escalate according to perfusion and support trajectory as well as blood pressure.

Case sources: [2] [11]